SK122099A3 - Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use - Google Patents

Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use Download PDF

Info

Publication number
SK122099A3
SK122099A3 SK1220-99A SK122099A SK122099A3 SK 122099 A3 SK122099 A3 SK 122099A3 SK 122099 A SK122099 A SK 122099A SK 122099 A3 SK122099 A3 SK 122099A3
Authority
SK
Slovakia
Prior art keywords
cyclobutyl
dihydrothiazole
optionally substituted
carbon atoms
dichlorophenyl
Prior art date
Application number
SK1220-99A
Other languages
English (en)
Slovak (sk)
Inventor
Sharon Cheetham
Frank Kerrigan
Colin Gerhart Pryce Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of SK122099A3 publication Critical patent/SK122099A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1220-99A 1997-03-15 1998-03-09 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use SK122099A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705428.2A GB9705428D0 (en) 1997-03-15 1997-03-15 Therapeutic agents
PCT/EP1998/001358 WO1998041528A1 (en) 1997-03-15 1998-03-09 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use

Publications (1)

Publication Number Publication Date
SK122099A3 true SK122099A3 (en) 2000-05-16

Family

ID=10809320

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1220-99A SK122099A3 (en) 1997-03-15 1998-03-09 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use

Country Status (22)

Country Link
US (1) US6187802B1 (de)
EP (1) EP0970090B1 (de)
JP (1) JP2001515501A (de)
KR (1) KR20000076190A (de)
CN (1) CN1255136A (de)
AT (1) ATE218573T1 (de)
AU (1) AU6728898A (de)
BG (1) BG103754A (de)
BR (1) BR9808254A (de)
CA (1) CA2283438A1 (de)
DE (1) DE69805781D1 (de)
GB (1) GB9705428D0 (de)
HU (1) HUP0001508A3 (de)
ID (1) ID22636A (de)
IL (1) IL131515A0 (de)
NO (1) NO994452D0 (de)
NZ (1) NZ337378A (de)
PL (1) PL335696A1 (de)
SK (1) SK122099A3 (de)
TR (1) TR199902291T2 (de)
WO (1) WO1998041528A1 (de)
ZA (1) ZA982134B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856965A1 (de) * 1998-12-10 2000-06-15 Bayer Ag Substituierte 2-Imino-thiazoline
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
WO2000056312A1 (en) 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
GB9911881D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
GB9911863D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0005789D0 (en) * 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
US7211407B2 (en) * 2003-07-15 2007-05-01 Chan Test, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050054010A1 (en) * 2003-07-15 2005-03-10 Brown Arthur M. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050208595A1 (en) * 2004-03-19 2005-09-22 Brown Arthur M High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
KR101294014B1 (ko) * 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
KR100752757B1 (ko) * 2006-04-05 2007-08-29 한국과학기술연구원 2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CN102160865A (zh) 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク. (r)−プラミペキソールを使用した組成物並びにその方法
KR101049935B1 (ko) * 2008-12-03 2011-07-15 한국과학기술연구원 신규한 티아졸린계 화합물 및 이를 포함하는 t-형 칼슘 채널 저해제
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
RS67279B1 (sr) 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3033081B1 (de) 2013-08-13 2021-05-12 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von chronischer nesselsucht
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347248A (en) * 1981-03-23 1982-08-31 American Cyanamid Company 2,3-Disubstituted-thiazolo[3,2-a]pyrimidines
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
FR2612187B1 (fr) * 1987-03-12 1989-07-21 Sanofi Sa Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
EP0600489B1 (de) * 1992-12-04 1996-11-06 Sumitomo Chemical Company Limited Verfahren zur Herstellung von 2-Iminothiazolin-Derivaten und Verfahren zur Herstellung ihrer Zwischenprodukte
EP0683160A1 (de) 1994-04-04 1995-11-22 Sumitomo Chemical Company, Limited Iminothiazolin-Derivate und diese als aktive Bestandteile enthaltende Herbizide
GB9513467D0 (en) * 1995-07-01 1995-09-06 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
TR199902291T2 (xx) 1999-12-21
CA2283438A1 (en) 1998-09-24
HUP0001508A3 (en) 2003-01-28
DE69805781D1 (de) 2002-07-11
CN1255136A (zh) 2000-05-31
BG103754A (bg) 2000-06-30
HUP0001508A2 (hu) 2001-01-29
PL335696A1 (en) 2000-05-08
NO994452L (no) 1999-09-14
GB9705428D0 (en) 1997-04-30
ID22636A (id) 1999-12-02
WO1998041528A1 (en) 1998-09-24
ZA982134B (en) 1999-09-13
IL131515A0 (en) 2001-01-28
BR9808254A (pt) 2000-05-16
AU6728898A (en) 1998-10-12
US6187802B1 (en) 2001-02-13
NO994452D0 (no) 1999-09-14
EP0970090B1 (de) 2002-06-05
EP0970090A1 (de) 2000-01-12
KR20000076190A (ko) 2000-12-26
NZ337378A (en) 2001-01-26
JP2001515501A (ja) 2001-09-18
ATE218573T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
US6187802B1 (en) Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use
RU2593756C2 (ru) Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе
SK16852001A3 (sk) Tiazolové deriváty a farmaceutické kompozície ich obsahujúce
IL266962A (en) Troyilphenoxide Benzamide Capaide Opioids Legends, Preparations Containing Them and Their Uses
PL190721B1 (pl) Pochodna alkiloaminobenzotiazolu i alkiloaminobenzoksazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna
SK16842001A3 (sk) Substituované imidazotiazoly ako antidepresívne prostriedky
JPH04234860A (ja) チアジン(又はオキサジン)誘導体、その製法及びその合成中間体
AU708789B2 (en) Condensed thiazole derivatives, having 5-HT receptor affinity
TWI376373B (en) Crystalline base of a pharmaceutical compound
JP4590102B2 (ja) 医薬としての三環性δ3−ピペリジン類
SK1382001A3 (en) N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES, PRODUCTION AND USEì (54) THEREOF
CZ9903260A3 (cs) Terapeutická činidla
US6458821B1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
CA3045242C (en) Heteroarylphenoxy benzamide kappa opioid ligands
MXPA97009509A (en) Therapeutic agents
CA2340168A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
JPS61251676A (ja) 新規トリメトキシベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物